Aktuellt
SENASTE
FluoGuide announced successful interim results in head and neck cancer, with 100% (12/12) of patients' tumours illuminated by FG001 - a small de-risking event, in our view. Together with results from glioma and lung cancer, the data offers further validation that FG001 has broad utility in fluorescence-guided surgery (FGS). Dose-finding is still underway, and full topline is expected in H2/23, with proof-of-concept efficacy data in FGS for glioblastoma also due during H2/23.
LÄS MER
